Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. BICO Group AB (publ)
  6. News
  7. Summary
    BICO   SE0013647385


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Cellenion Announces Co-Marketing Agreement for Single Cell Mass Spectrometry-Based Proteomics Analysis

11/15/2021 | 08:31am EST

The collaboration, with Thermo Fisher Scientific, will provide a full workflow, from sample to results, for scientists performing multiplexed single cell proteomics analyses

Cellenion, a BICO company, announced today a co-marketing agreement with Thermo Fisher Scientific to advance single cell proteomics analyses. The goal of the partnership is to combine Cellenion's cellenONE® and proteoCHIPTM with Thermo Fisher's TMT multiplexing technologies and Thermo Scientific(TM) Orbitrap(TM) mass spectrometers to deliver complete solutions, from single cell isolation and automated sample preparation through to mass spectrometry (MS)-based proteomics analysis on single cells.

Cellenion has developed cellenONE®, a system combining image-based single cell isolation and nanoliter dispensing to perform every step of the sample preparation using a single device, and proteoCHIP 12*16, a dedicated consumable for automated and loss-less sample preparation prior to multiplexed single cell proteomics analyses.

Thermo Scientific Orbitrap mass spectrometers in combination with enhanced sensitivity and throughput by multiplexing cells with TMT isobaric labelling allows their platforms to deliver more proteins per cell and from tens to hundreds of cells per day, going beyond one cell at a time.

With single cell proteomics providing vital information on the state of individual cells within heterogeneous environments, the combination of this sample preparation technology with Thermo Fisher's TMT multiplexing technologies and Orbitrap mass spectrometers will provide researchers with powerful tools to standardize MS-based single cell proteomics workflows.

"This partnership will accelerate development of novel solutions for sample preparation prior to multiplexed single cell proteomics analyses," says Dr. Guilhem Tourniaire, Managing Director at Cellenion. "By automating sample preparation, we hope to encourage the adoption of these revolutionary methods, bring a new dimension to Biology, and ultimately, contribute to the future of health."

"Single cell proteomics has the potential to disrupt many areas of biology through granular and precise research. We know our customers want to do single cell proteomics because they are on a mission to advance human health," says Daniel Lopez Ferrer, Director of the Proteomics Program at Thermo Fisher. "They know that to perform single cell analysis at scale our mass spectrometers in combination with TMT multiplexing is the way to go. Partnering with Cellenion enables us to deliver researchers a convenient full end to end solution to perform single cell proteomics analysis that will accelerate their progress mastering the complexities of biology."

For more information about Cellenion's single cell mass spectrometry-based proteomics offering, please visit: www.cellenion.com/applications/single-cell-proteomics/

This information was submitted for publication, through the agency of the contact persons set out above, on November 15, 2021, at 2:30 pm (CET).

For more information, please contact
Isabelle Ljunggren, Head of Communications
Phone: +46 (0) 708 30 08 90
Email: il@bico.com

BICO Press office   
Phone (US) 
Riley Munks, PR Manager (650) 863-6699  
Alyssa D'Orazio, PR Manager (617) 634-9601 
Email: press@bico.com

About BICO

Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better. 

With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health. 

The Group's instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com

About Cellenion

Cellenion offers solutions and technologies for controlled cell dispensing with applications in the fields of single cell and single cellular aggregates isolation. Our systems allow high throughput, image-based automated dispensing of single cells and/or cell aggregates onto any substrates of choice. Together with a range of dedicated consumables, the solutions enable miniaturization of sample preparation protocols on the same instrument before downstream analysis. With no dead volumes and outstanding recovery rates, Cellenion's platforms offer unique capacities for applications including single-cell omics, rare cells, cell line development, drug screening and 3D model development. Cellenion operates from Lyon, France. The company is a subsidiary of SCIENION GmbH and its products are sold by SCIENION worldwide.

Cellenion Contact

Cellenion SASU
60 Avenue Rockefeller
Bioserra 2
F-69008 Lyon
Phone: +33 (0)9 86 48 70 70
Email: contact@cellenion.com



(c) 2021 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
BICO GROUP AB (PUBL) -4.93% 204.4 Delayed Quote.-22.61%
THERMO FISHER SCIENTIFIC -1.16% 587.89 Delayed Quote.-10.86%
All news about BICO GROUP AB (PUBL)
01/13Center for Contemporary Sciences Partners with BICO to Modernize Medical Research and D..
01/13BICO : Partners with the Center for Contemporary Sciences to Reduce Animal Testing in Life..
01/12BICO Group Denies Infringement Of Organovo's US Patents
01/11Statement from BICO regarding counterclaims in patent lawsuit by Organovo against group..
2021Wallenstam Leases Office Properties In Sweden's Gothenburg Area
2021BICO Group Closes $170 Million Purchase of US Software Firm Biosero
2021BICO completes the acquisition of Biosero
2021BICO GROUP AB (OM : BICO) completed the acquisition of Biosero Llc at an enterprise value ..
2021BICO moves to Nasdaq Stockholm's Large Cap Segment
2021Bico Acquires US Software Firm Biosero for $165 Million
More news
Sales 2021 1 264 M 139 M 139 M
Net income 2021 -82,2 M -9,03 M -9,03 M
Net cash 2021 4 281 M 470 M 470 M
P/E ratio 2021 -148x
Yield 2021 -
Capitalization 13 616 M 1 511 M 1 495 M
EV / Sales 2021 7,39x
EV / Sales 2022 4,43x
Nbr of Employees 997
Free-Float 65,2%
Duration : Period :
BICO Group AB (publ) Technical Analysis Chart | BICO | SE0013647385 | MarketScreener
Technical analysis trends BICO GROUP AB (PUBL)
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 1
Last Close Price 215,00 SEK
Average target price 545,00 SEK
Spread / Average Target 153%
EPS Revisions
Managers and Directors
Erik Paul Gatenholm Chief Executive Officer & Director
Gusten Danielsson Chief Financial Officer
Carsten Nils Erik Browall Chairman
Hector Daniel Martinez Avila Chief Technology Officer
Niclas Emanuelsson Head-Global Operations
Sector and Competitors
1st jan.Capi. (M$)
BICO GROUP AB (PUBL)-22.61%1 511